Cocaine Use Disorder and Cortical Dopamine

• Status: Completed
• Trial end date: 2020-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The goal of this study is to use [C-11]FLB 457 and amphetamine (oral, 0.5 mg/kg) to measure cortical dopamine transmission in cocaine dependent individuals and healthy controls

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of Pittsburgh
• Collaborator: National Institute on Drug Abuse (NIDA)
• Treatments: Amphetamine; Cocaine; Dextroamphetamine; Dopamine; Dopamine Agents; FLB 457

Criteria

Subjects with Cocaine Dependence INCLUSION CRITERIA

1. Males or Females 18-40

2. Fulfill Diagnostic and Statistical Manual (DSM-IV) Diagnosis for Cocaine Dependence

3. Medically Healthy MAJOR EXCLUSIONS

1. Major medical, psychiatric, co-morbid drug & alcohol use disorders 2. Pregnancy or lactation, 3. Contraindications to MRI 4. Currently employed as radiation worker; or participation in radioactive drug research protocols within the previous year 5. Family History of a psychotic illness or manic episode in first-degree relatives

Healthy Subjects INCLUSION CRITERIA

1. Males or Females 18-40

2. Absence of present or past psychiatric conditions (including alcohol or drug dependence)

3. A negative urine drug screen

4. Medically Healthy

MAJOR EXCLUSIONS

1. Any medical, psychiatric, co-morbid drug & alcohol use disorders

2. Pregnancy or lactation,

3. Contraindications to MRI

4. Currently employed as radiation worker; or participation in radioactive drug research protocols within the previous year

5. Family History of a psychotic illness or manic episode, or drug and alcohol Abuse/Dependence in first-degree relatives